Feng Sheng, Cleary Yumi, Parrott Neil, Hu Pei, Weber Cornelia, Wang Yongqing, Yin Ophelia Q P, Shi Jun
Roche Innovation Center Shanghai, Building 6, Lane 917, Ha Lei Road, Pudong, Shanghai, China.
Eur J Clin Pharmacol. 2015 May;71(5):617-24. doi: 10.1007/s00228-015-1834-y. Epub 2015 Mar 24.
The purpose of this study is to evaluate the ethnicity-specific population models in the SimCYP Simulator® for prediction of omeprazole clearance with attention to differences in the CYP2C19 metabolic pathway.
The SimCYP® models incorporating Caucasian, Chinese, and Japanese population-specific demographic, physiological, and enzyme data were applied to simulate omeprazole pharmacokinetics. Published pharmacokinetic data of omeprazole after intravenous or oral administration in Caucasian, Chinese, and Japanese were used for the evaluation.
Following oral administration, the ratio of the predicted to observed geometric mean of omeprazole clearance in Caucasian extensive metabolizers (EMs) was 0.88. The ratios in Chinese EMs were 1.16 and 0.99 after intravenous and oral administration, respectively. The ratios in Japanese EMs were 0.88 and 0.71 after intravenous and oral administration, respectively. Significant differences (2-fold) in the observed oral clearance of omeprazole were identified between Caucasian and Asian (Chinese and Japanese) EMs while the observed oral and intravenous clearances of omeprazole were similar between Chinese and Japanese EMs. Physiologically based pharmacokinetics (PBPK) models within SimCYP accurately predicted the difference in the observed oral clearance between Caucasian and Chinese EMs but overpredicted the difference between Caucasians and Japanese EMs due to under-prediction of oral clearance in Japanese EMs.
The PBPK model within SimCYP adequately predicted omeprazole clearance in Caucasian, Chinese, and Japanese EMs and the 2-fold differences in clearance of omeprazole between Caucasian and Asian EMs. This may lead to early identification of ethnic sensitivity in clearance and the need for different dosing regimens in a specific ethnic group for substrates of CYP2C19 which can support the rational design of bridging clinical trials.
本研究旨在评估SimCYP Simulator®中特定种族的人群模型,以预测奥美拉唑清除率,并关注CYP2C19代谢途径的差异。
应用包含白种人、中国人和日本人特定种族的人口统计学、生理学和酶数据的SimCYP®模型来模拟奥美拉唑的药代动力学。使用已发表的白种人、中国人和日本人静脉注射或口服奥美拉唑后的药代动力学数据进行评估。
口服给药后,白种人广泛代谢者(EMs)中奥美拉唑清除率预测几何均值与观察几何均值的比值为0.88。中国人EMs静脉注射和口服给药后的比值分别为1.16和0.99。日本人EMs静脉注射和口服给药后的比值分别为0.88和0.71。在白种人和亚洲人(中国人和日本人)EMs之间,观察到的奥美拉唑口服清除率存在显著差异(2倍),而中国人和日本人EMs之间观察到的奥美拉唑口服和静脉清除率相似。SimCYP中的基于生理学的药代动力学(PBPK)模型准确预测了白种人和中国人EMs之间观察到的口服清除率差异,但由于对日本人EMs口服清除率预测不足,高估了白种人和日本人EMs之间的差异。
SimCYP中的PBPK模型充分预测了白种人、中国人和日本人EMs中奥美拉唑的清除率以及白种人和亚洲人EMs之间奥美拉唑清除率的2倍差异。这可能有助于早期识别清除率的种族敏感性以及特定种族群体中CYP2C19底物不同给药方案的必要性,从而支持桥接临床试验的合理设计。